Literature DB >> 23576104

Characterization of TRIP6-dependent nasopharyngeal cancer cell migration.

Jie Fei1, Jihong Li, Sunan Shen, Weidong Zhou.   

Abstract

Nasopharyngeal carcinoma (NPC) is a leading malignancy most often reported in endemic areas such as in Southeast Asia and the Mediterranean area. NPC remains as a major challenge for clinical management largely due to its high propensity for cancer invasion, metastasis, and recurrence. Therefore, control of NPC cell motility stands as a major obstacle for successful NPC management. The current study sought to identify a new regulator for NPC cell motility in light of previous data showing a similar role of thyroid receptor interactor protein 6 (TRIP6) in other cancer cell types. Results showed that TRIP6 is up-regulated in NPC cells as compared to normal nasopharyngeal epithelial cells. Moreover, TRIP6 overexpression/knockdown results in significant enhancement/inhibition of NPC cell migration, respectively. Interestingly, data also suggested that TRIP6 Y55E (tyrosine 55 to glutamic acid) mutant can promote cell migration more efficiently than wild type does, while Y55A (tyrosine 55 to alanine) mutant has no effects on cell migration as demonstrated with different methodology. Consistently, we also found that c-Src physically interacts with TRIP6, which suggests its potential role as a TRIP6 kinase. Taken together, these data suggested that TRIP6 is involved in the regulation of NPC cell motility, and phosphorylation of tyrosine 55 residue plays an important regulatory role for this event. These data highlight the importance of TRIP6 as a novel regulator of NPC cell motility, which warrants a good basis for further investigation on the underlying mechanism by which TRIP6 exerts this effect and the pathophysiological role TRIP6 plays in vivo.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23576104     DOI: 10.1007/s13277-013-0780-5

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  31 in total

1.  Clinical outcomes and patterns of failure after intensity-modulated radiotherapy for nasopharyngeal carcinoma.

Authors:  Wai Tong Ng; Michael C H Lee; Wai Man Hung; Cheuk Wai Choi; Kin Chung Lee; Oscar S H Chan; Anne W M Lee
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-05-06       Impact factor: 7.038

2.  [Down-regulation of TRIP6 expression induces actin cytoskeleton rearrangements in human carcinoma cell lines].

Authors:  O A Gur'ianova; A A Sablina; P M Chumakov; E I Frolova
Journal:  Mol Biol (Mosk)       Date:  2005 Sep-Oct

Review 3.  From the membrane to the nucleus and back again: bifunctional focal adhesion proteins.

Authors:  Martial Hervy; Laura Hoffman; Mary C Beckerle
Journal:  Curr Opin Cell Biol       Date:  2006-09-05       Impact factor: 8.382

Review 4.  Role of intermediate filaments in migration, invasion and metastasis.

Authors:  M J Hendrix; E A Seftor; Y W Chu; K T Trevor; R E Seftor
Journal:  Cancer Metastasis Rev       Date:  1996-12       Impact factor: 9.264

5.  The human TRIP6 gene encodes a LIM domain protein and maps to chromosome 7q22, a region associated with tumorigenesis.

Authors:  J Yi; M C Beckerle
Journal:  Genomics       Date:  1998-04-15       Impact factor: 5.736

6.  Targeting the yin and the yang: combined inhibition of the tyrosine kinase c-Src and the tyrosine phosphatase SHP-2 disrupts pancreatic cancer signaling and biology in vitro and tumor formation in vivo.

Authors:  Evan G Gomes; Sarah F Connelly; Justin M Summy
Journal:  Pancreas       Date:  2013-07       Impact factor: 3.327

Review 7.  Definitive treatment of metastatic nasopharyngeal carcinoma: Report of 5 cases with review of literature.

Authors:  Jeremy Setton; Suzanne Wolden; Nicola Caria; Nancy Lee
Journal:  Head Neck       Date:  2010-11-04       Impact factor: 3.147

8.  PTPL1/FAP-1 negatively regulates TRIP6 function in lysophosphatidic acid-induced cell migration.

Authors:  Yun-Ju Lai; Weei-Chin Lin; Fang-Tsyr Lin
Journal:  J Biol Chem       Date:  2007-06-25       Impact factor: 5.157

9.  Cell cycle regulated phosphorylation of LIMD1 in cell lines and expression in human breast cancers.

Authors:  Christopher Jack Huggins; Irene L Andrulis
Journal:  Cancer Lett       Date:  2008-04-24       Impact factor: 8.679

Review 10.  The role of E-cadherin and scatter factor in tumor invasion and cell motility.

Authors:  J Behrens; K M Weidner; U H Frixen; J H Schipper; M Sachs; N Arakaki; Y Daikuhara; W Birchmeier
Journal:  EXS       Date:  1991
View more
  5 in total

1.  Overexpression of TRIP6 promotes tumor proliferation and reverses cell adhesion-mediated drug resistance (CAM-DR) via regulating nuclear p27(Kip1) expression in non-Hodgkin's lymphoma.

Authors:  Xiaobing Miao; Xiaohong Xu; Yaxun Wu; Xinghua Zhu; Xudong Chen; Chunsun Li; Xiaoyun Lu; Yali Chen; Yushan Liu; Jieyu Huang; Yuchan Wang; Song He
Journal:  Tumour Biol       Date:  2015-08-23

2.  TRIP6 inhibits Hippo signaling in response to tension at adherens junctions.

Authors:  Shubham Dutta; Sebastian Mana-Capelli; Murugan Paramasivam; Ishani Dasgupta; Heather Cirka; Kris Billiar; Dannel McCollum
Journal:  EMBO Rep       Date:  2017-12-08       Impact factor: 8.807

3.  Novel metastatic models of esophageal adenocarcinoma derived from FLO-1 cells highlight the importance of E-cadherin in cancer metastasis.

Authors:  David S Liu; Sanne J M Hoefnagel; Oliver M Fisher; Kausilia K Krishnadath; Karen G Montgomery; Rita A Busuttil; Andrew J Colebatch; Matthew Read; Cuong P Duong; Wayne A Phillips; Nicholas J Clemons
Journal:  Oncotarget       Date:  2016-12-13

4.  LINC00675 is a prognostic factor and regulates cell proliferation, migration and invasion in glioma.

Authors:  Zhibing Li; Yijian Li; Qibai Wang
Journal:  Biosci Rep       Date:  2018-09-19       Impact factor: 3.840

5.  TRIP6 regulates the proliferation, migration, invasion and apoptosis of osteosarcoma cells by activating the NF-κB signaling pathway.

Authors:  Wei Liu; Li Cheng; Qingning Li; Juehua Jing
Journal:  Exp Ther Med       Date:  2020-01-22       Impact factor: 2.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.